We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn about our cookie policy.
GenScript Gencrispr™ Cas9 V1.1; 1mg
List Price $1,025.00 Your Price $1,025.00
GenScript Gencrispr™ Cas9 V1.11mg - GSCRPT (Additional S&H or Hazmat Fees May Apply)
NETA PART: GSCRPT-Z03701-1
MFG.PART: Z03701-1
UNSPSC: 12352204
Manufacturer: GenScript USA Inc
Description
The GenCRISPR™Cas9 v1.1 can be formedwith the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNPcomplex to perform gene editing has been shown to reduce the challengesencountered with other CRISPR gene editing techniques such as viral and plasmiddelivery. Challenges include off-target effects, cell viability and transcription/translationalchallenges. GenCRISPR™Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmidencoding the Cas9 gene from Streptococcuspyogenes with a biparticle nucleus localization signal (BPNLS) at bothN-terminal and C-terminal. It has been reported that BPNLS is able to improvethe gene editing efficiency. |
Note
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Applications
| gRNA-dependent double-stranded DNA cleavage |
Properties
| Source | RecombinantCas9 with a BPNLS at both N-terminal and C-terminal expressed by E.coli |
| Species | Streptococcus pyogenes |
| Tag | Tag-free |
| Molecular Weight | ~160kDa |
| Concentration | 4 mg/ml |
| Active temperature | ThisCas9 is active at 37 °C. |
| Formulation | Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1mM EDTA, 50% glycerol, pH 8.0. |
| Storage & Stability | This product remains stable for up to 12 months at -20°C. Avoid repeatedfreeze-thaw cycles. |
| Key Features | High knockoutefficiencies: Consistent high editing efficiency in in-vitro and in-vivo. Tag-free: No extra tagamino acid. DNA-free: No externalDNA added to the system. |
Quality Control Specifications
| Appearance | Clear,colorless liquid |
| Purity | ≥ 90%as analyzed by SDS-PAGE |
| Concentration by A280 | 4mg/ml±10% |
| Bioactivity (in vitro) | ≥ 90% |
| Residual DNase | Non-specificDNase activity |
| Residual RNase | Non-specificRNase activity |
| Endotoxin Level | ≤100 EU/mg as analyzed by gel clotting method |
Background
| References | 1. Liu, Xinyi, et al. "Improving editingefficiency for the sequences with NGH PAM using xCas9-derived baseeditors." Molecular Therapy-Nucleic Acids 17 (2019): 626-635. 2. Pollard, Victoria W., et al."A novel receptor-mediated nuclear protein import pathway."Cell86.6(1996): 985-994. 3. Koblan, Luke W., et al."Improving cytidine and adenine base editors by expression optimizationand ancestral reconstruction."Nature biotechnology36.9(2018): 843-846. |
| SKU | GSCRPT-Z03701-1 |
|---|---|
| Supplier Part Number | Z03701-1 |
| UM | EA |
| UNSPSC | 12352204 |
| Manufacturer | GenScript USA Inc |
| Temperature | This product remains stable for up to 12 months at -20°C. Avoid repeatedfreeze-thaw cycles. |
| ProductLine | GSCRPT |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.000000 |
| Lead Time | 7 |
| Hazardous | N |
| Energy Star | No |
| Green | No |
| Controlled | N |